Yahoo
    Swiss - Delayed Quote CHF

    Tecan Group AG (TECN.SW)

    Get top stock picks
    194.90 -0.70 (-0.36%)
    At close: September 4 at 5:31:48 PM GMT+2
    Get top stock picks
    Loading Chart for TECN.SW
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

    A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
    Barrons.com 1d ago
    Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

    Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
    BioPharma Dive 1d ago
    Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

    Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
    GlobeNewswire 2d ago
    NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?

    NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
    Stocktwits 2d ago
    Novartis, Ionis Tumble On Surprise Flop For Heart Drug

    Novartis, Ionis Tumble On Surprise Flop For Heart Drug
    Investor's Business Daily 2d ago
    Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

    Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
    Business Wire 2d ago
    Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

    Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
    GlobeNewswire 2d ago
    ORLEN and partners launch Baltic Energy Initiative

    ORLEN and partners launch Baltic Energy Initiative
    Energy Monitor 2d ago
    Is Novartis (SWX:NOVN) Overvalued After Its Phase III Remibrutinib Win?

    Is Novartis (SWX:NOVN) Overvalued After Its Phase III Remibrutinib Win?
    Simply Wall St. 2d ago
    Novartis (NVS)’s Latest Basel Move Signals a Shift in Strategic Priorities

    Novartis (NVS)’s Latest Basel Move Signals a Shift in Strategic Priorities
    Insider Monkey 3d ago
    dorma+kaba Holding AG (DRMKY) (FY 2026) Earnings Call Highlights: Record Margins and Strategic ...

    dorma+kaba Holding AG (DRMKY) (FY 2026) Earnings Call Highlights: Record Margins and Strategic ...
    GuruFocus.com 3d ago

    Related Tickers

    7747.T
    ALCz.XC
    COLOBc.XC
    STMN.SW
    CTEC.L
    YPSN.SW
    SRT3.DE
    ALC.SW
    NVST
    RGEN
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: